Get started
Work

108O Thymic health is associated with immunotherapy outcomes in patients with cancer

Year: 2025
Type: article
DOI: 10.1016/j.annonc.2025.08.542
Authors: S. Bernatz, S. Pai, V. Prudente, A. Kjær, A. Di Federico, L. Dyrskjot, L. Nürnberg, J. Alessi, P.A. Ott, E. Sharon, C.Z. Abbosh, D. Bitterman, M.M. Awad, B. Ricciuti, C. Swanton, M. Jamal-Hanjani, N.J. Birkbak, H. Aerts
Institutions: Brigham and Women's Hospital, Aarhus University Hospital, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Dana-Farber Cancer Institute, National Cancer Institute, AstraZeneca (United Kingdom), Memorial Sloan Kettering Cancer Center, The Francis Crick Institute, University College London, Harvard University
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Harvard Catalyst, Regeneron Pharmaceuticals, Francis Crick Institute, Astex Pharmaceuticals, Relay Therapeutics, UroGen Pharma, Natera, Invitae, Coherus Biosciences, Cancer Research UK, European Commission, Deutsche Forschungsgemeinschaft, National Institutes of Health, Genentech, EMD Serono, European Research Council
Awards: G4879113525, G5024937287, G6011549775, Deep Learning und radiologische Biomarker für die nichtinvasive Prognoseprädiktion immunonkologisch therapierter Patientinnen und Patienten mit diversen Tumorarten., G9000000961, G9000012061, G9000028293, G9000041608, G9000049100, G9000081776, G9000220778, G9000308345
OpenAlex ID: W4415939814
FWCI: 0.729
Cites:
Cited by: 2
Related to: